Imaging small molecule-induced endosomal escape of siRNA

[1]  R. Juliano,et al.  Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Don't. , 2018, Nucleic acid therapeutics.

[2]  A. Khvorova,et al.  Efficient Gene Silencing in Brain Tumors with Hydrophobically Modified siRNAs , 2018, Molecular Cancer Therapeutics.

[3]  S. D. De Smedt,et al.  Repurposing cationic amphiphilic drugs as adjuvants to induce lysosomal siRNA escape in nanogel transfected cells , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[4]  M. Zerial,et al.  Rab5 and Alsin regulate stress-activated cytoprotective signaling on mitochondria , 2017, bioRxiv.

[5]  B. Hoflack,et al.  L-leucyl-L-leucine methyl ester does not release cysteine cathepsins to the cytosol but inactivates them in transiently permeabilized lysosomes , 2017, Journal of Cell Science.

[6]  Craig L Duvall,et al.  Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing , 2017, Proceedings of the National Academy of Sciences.

[7]  M. DiFiglia,et al.  Synthesis and Evaluation of Parenchymal Retention and Efficacy of a Metabolically Stable O-Phosphocholine-N-docosahexaenoyl-l-serine siRNA Conjugate in Mouse Brain. , 2017, Bioconjugate chemistry.

[8]  Mark Ellisman,et al.  A Rab5 endosomal pathway mediates Parkin-dependent mitochondrial clearance , 2017, Nature Communications.

[9]  J. Carette,et al.  PLA2G16 represents a switch between entry and clearance of Picornaviridae , 2017, Nature.

[10]  B. Bettencourt,et al.  A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 , 2017, The New England journal of medicine.

[11]  I. V. Chernikov,et al.  Cholesterol-Containing Nuclease-Resistant siRNA Accumulates in Tumors in a Carrier-free Mode and Silences MDR1 Gene , 2017, Molecular therapy. Nucleic acids.

[12]  D. Egan,et al.  Discovery of Small Molecules That Induce Lysosomal Cell Death in Cancer Cell Lines Using an Image-Based Screening Platform. , 2016, Assay and drug development technologies.

[13]  S. Dowdy,et al.  Enhancing Endosomal Escape for Intracellular Delivery of Macromolecular Biologic Therapeutics , 2016, Scientific Reports.

[14]  Hong Cao,et al.  Guanabenz (Wytensin™) selectively enhances uptake and efficacy of hydrophobically modified siRNAs , 2015, Nucleic acids research.

[15]  J. Nylandsted,et al.  Visualizing Lysosomal Membrane Permeabilization by Fluorescent Dextran Release. , 2015, Cold Spring Harbor protocols.

[16]  J. Lieberman,et al.  Gene Knockdown by EpCAM Aptamer–siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells , 2015, Molecular Cancer Therapeutics.

[17]  I. Gromova,et al.  Sensitive detection of lysosomal membrane permeabilization by lysosomal galectin puncta assay , 2015, Autophagy.

[18]  Herbert Waldmann,et al.  Identification of siRNA delivery enhancers by a chemical library screen , 2015, Nucleic acids research.

[19]  Judy Lieberman,et al.  Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown , 2015, Nature Biotechnology.

[20]  R. L. Juliano,et al.  High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides , 2015, Nucleic acids research.

[21]  Amy Chan,et al.  Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. , 2014, Journal of the American Chemical Society.

[22]  V. Turk,et al.  Siramesine triggers cell death through destabilisation of mitochondria, but not lysosomes , 2013, Cell Death and Disease.

[23]  Christer S. Ejsing,et al.  Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. , 2013, Cancer cell.

[24]  Sarah Seifert,et al.  Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape , 2013, Nature Biotechnology.

[25]  Darren H. Wakefield,et al.  Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. , 2012, Nucleic acid therapeutics.

[26]  F. Randow,et al.  Galectin-8 targets damaged vesicles for autophagy to defend cells against bacterial invasion , 2011, Nature.

[27]  A. Sachs,et al.  Biodistribution of Small Interfering RNA at the Organ and Cellular Levels after Lipid Nanoparticle-mediated Delivery , 2011, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[28]  K. G. Rajeev,et al.  Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  G. Kroemer,et al.  Lysosomal membrane permeabilization in cell death , 2008, Oncogene.

[30]  M. Stoffel,et al.  Mechanisms and optimization of in vivo delivery of lipophilic siRNAs , 2007, Nature Biotechnology.

[31]  Darren H. Wakefield,et al.  Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes , 2007, Proceedings of the National Academy of Sciences.

[32]  Yong Wang,et al.  Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras , 2006, Nature Biotechnology.

[33]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.

[34]  Thomas Farkas,et al.  Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. , 2005, Cancer research.

[35]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[36]  Yoshiro Kobayashi,et al.  Mechanism of apoptosis induced by a lysosomotropic agent, L-Leucyl-L-Leucine methyl ester , 1999, Apoptosis.

[37]  G. Kroemer,et al.  Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine , 2003, Oncogene.

[38]  R. Medzhitov,et al.  Retroviral delivery of small interfering RNA into primary cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  R. Bernards,et al.  Stable suppression of tumorigenicity by virus-mediated RNA interference. , 2002, Cancer cell.

[40]  Kate S. Carroll,et al.  Role of Rab9 GTPase in Facilitating Receptor Recruitment by TIP47 , 2001, Science.

[41]  S. Kain,et al.  Generation of Destabilized Green Fluorescent Protein as a Transcription Reporter* , 1998, The Journal of Biological Chemistry.

[42]  B. Hillman.  What we know and what we don't. , 1991, Investigative radiology.

[43]  P. Lipsky,et al.  Mechanism of L-leucyl-L-leucine methyl ester-mediated killing of cytotoxic lymphocytes: dependence on a lysosomal thiol protease, dipeptidyl peptidase I, that is enriched in these cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[44]  F. Maxfield.  Weak bases and ionophores rapidly and reversibly raise the pH of endocytic vesicles in cultured mouse fibroblasts , 1982, The Journal of cell biology.

[45]  T. Springer,et al.  Mac-2, a novel 32,000 Mr mouse macrophage subpopulation-specific antigen defined by monoclonal antibodies. , 1982, Journal of immunology.